Kill drug-tolerant persisters through ferroptosis
The cells that survive targeted therapy change shape and become unusually dependent on an antioxidant enzyme, GPX4. Hitting them in that window might stop resistance before it evolves.
Persister cells after EGFR, ALK, or BRAF inhibition are mesenchymal and GPX4-dependent (Viswanathan/Hangauer 2017); no drug-like GPX4 inhibitor exists, but xCT inhibitors, cyst(e)inase, and radiotherapy induce lipid peroxidation.
Pages like this
not linked directly; found by shared links- IdeaAttack extrachromosomal DNA, the engine of oncogene amplification
Shares Clonal evolution & minimal residual disease, Stanford Health Care / Stanford Cancer Institute, EGFR, Liquid biopsy (ctDNA) and the tags mechanism, open-question.
- IdeaIntercept cancer at the field stage
Shares Clonal evolution & minimal residual disease, Non-small-cell lung cancer and the tags mechanism, open-question.
- IdeaGive immunotherapy in the morning
Shares Melanoma, Non-small-cell lung cancer and the tags mechanism, open-question.
- IdeaMicrobiome transplant as a routine immunotherapy adjunct
Shares Melanoma, Non-small-cell lung cancer and the tags mechanism, open-question.
- IdeaCut the nerve supply to tumours with old drugs
Shares Stanford Health Care / Stanford Cancer Institute and the tags mechanism, open-question.
- IdeaIs aneuploidy itself a druggable vulnerability?
Shares Stanford Health Care / Stanford Cancer Institute and the tags mechanism, open-question.
- IdeaWhich patients' blood clones will become leukaemia after treatment?
Shares Liquid biopsy (ctDNA) and the tags mechanism, open-question.
- IdeaShared splice-derived neoantigens as off-the-shelf vaccine targets
Shares Melanoma and the tags mechanism, open-question.